Whalesbook
Galeer share bazaar vich jo jadoo chal reha hai, us ton hatke, bade waale (seasoned) investors Radhakishan Damani ate late Rakesh Jhunjhunwala da estate ne Concord Biotech ate BF Utilities 'ch apni pakad banai rakhi hai. Ethe hun takan share apne sab ton uchhe star ton 55% ate 80% takan dig chukke han. Eh jang laggi lagdiyaan sharean 'ch unhan da vishwas, short-term market di uchal-kud naal vadhke, companies de andar-sarr (intrinsic) value ate mazboot operational strength 'te bharosa jatonda hai.
Concord Biotech: Margins 'te Dabav De Bawajood Mazboot Operations
Concord Biotech, jo fermentation-based APIs vich mahir hai, khaas kar immunosuppressants ate oncology de क्षेत्र 'ch, February 2026 takan lagbhag ₹12,800 crore da market capitalization rakhi baithi hai. September 2024 'ch apne peak ₹2,664 nu chuhan ton baad, share 55% ton vadh ke ₹1,100 de aas-paas aa gaya hai. Eh giravat Q3 FY26 de pehle teen mahineya'n vich sales ate EBITDA vich kami karan mili hai. Nawi Valthera injectable facility ate US subsidiary Stellon Biotech de high initial costs ne vi profitability 'te asar paya hai, jisda margin 'te tanav hai.
Par, Concord Biotech di operational strength vakhri hai. Isda Return on Capital Employed (ROCE) 28-30% hai, jo pharmaceutical industry de average 15% nu kafi piche chhad janda hai. Company lagbhag debt-free hai, jisda matlab hai ki interest da bojh nahi hai. Analyst generally 'Buy' rating de rahe ne, ate average target price ₹1,427 de aas-paas hai, hala'nki kuch ne haal hi vich target kam kitte han. Stock da Price-to-Earnings (P/E) ratio 36x te 40x de vich chal reha hai, jo Indian pharmaceutical industry de average 26.4x ton vadh hai. Eh dasda hai ki investors isdi mazboot capital efficiency layi premium de rahe han. Haal de quarterly results ne EPS ate revenues vich analystan diyan ummidaan nu miss kita hai.
BF Utilities: Leverage Ate Liabilities Da Samna
Dusri taraf, BF Utilities Ltd., jo wind power generation ate infrastructure vich kam kardi hai, ne is ton vadh ke giravat dekhi hai. Share ₹2,628 de peak ton 80% ton vadh ke February 2026 de ant tak ₹490-₹500 de aas-paas aa gaya hai. Pahile nau mahineya'n FY26 vich sales saal-dar-saal ghatdi rahi, par EBITDA ate net profit vich thoda izafa dekhan nu milia. Par, market isde significant risks nu discount kar reha hai. Sab ton vadda risk ₹500 crore di contingent liability hai jo subsidiary NECE de khilaaf arbitration award karan aayi hai. Company 'te 4.7x da debt-to-equity ratio hai, jo interest da bojh vadhaunda hai ate financial flexibility nu ghatonda hai.
Inna risks de bawajood, BF Utilities da historical ROCE mazboot hai, pichhle 10 saalan da average 18% hai, jo industry median 7% ton kafi vadh hai. Haal da P/E ratio 5x te 15x de vich hai, jo industry median 21x ton bahuta kam hai. Eh discount market di isdi balance sheet ate contingent liabilities baare sandeh nu dassda hai. Hal hi vich company ne SEBI naal listing norman da ulangan da ₹3.6 crore da mamla nipataya hai. Bharata da renewable energy 'te zor dena company layi faidamand ho sakda hai, par isdi apni financial structure ek vaddi chunauti hai.
Damani Te Jhunjhunwala Di Strategy: Sacha Vade Da Rakhwala
Radhakishan Damani di investment philosophy 'value investing', lambi soch, ate mazboot risk management 'te adrikh hai. Oh fundamentally mazboot, kam cyclical business jinha'n di capital efficiency vadhdi hai, ohna nu pasand karde han. Rakesh Jhunjhunwala da estate vi Concord Biotech 'ch share rakh ke short-term market movements ton vadh ke underlying value 'te bharosa dikha reha hai. Eh veteran investors lagda hai ki stock price performance ton vadh ke mazboot return on capital, manageable debt (ya debt-free huna Concord da mamla), ate future operational leverage di sambhavna nu mahatva dinde han. Lagda hai oh Concord Biotech 'ch margins di normalisation ate BF Utilities 'ch liabilities da hal kiven hunda hai, us te bet laga reha hai, te aj de giri huiyan kimatan nu exit karan di bajaaye mauke samajh reha hai.
Vichitra Vala Pehlu: Zaroori Risk
Par, is vishwas da ikk dooja pehlu vi hai. Concord Biotech da valuation, jithe high ROCE hai, 36-40x P/E 'te kuch zyada lagda hai jo pharmaceutical peers de 26-33x average ton vadh hai, jis karan eh earnings miss hon di soorat vich nazuk ho sakda hai. Q3 FY26 de earnings miss ne is chinta nu hor vadha ditta hai. BF Utilities da hal hor vadda hai. Isda 4.7x debt-to-equity ratio ek badi warning bell hai, jo interest costs te financial fragility da karan ban sakda hai. ₹500 crore di contingent liability ate haal hi vich SEBI settlement naale governance ate legal risks vi han jina nu market agghe rakh reha hai. Pichhle 5 saalan vich company di sales growth -0.71% CAGR rahi hai ate pichhle 3 saalan vich ROE sirf 7.32% raha hai, jo isdi outlook nu hor kharaab karde han.
Agge Ki Dikhda Hai?
Halle takan, analyst Concord Biotech layi agli 3 saalan vich 17-24% takan annual revenue growth ate 23.7% EPS growth da anuman laga rahe han. Consensus target price current levels ton 30% takan upside da ishaara karda hai. Indian pharmaceutical sector vi domestic demand ate global relevance karan vadhda dikh reha hai. Dusri taraf, BF Utilities layi koi khaas agge diyan tarikh diyan analystan diyan estimations nahi milian. Company power generation sector vich kam kardi hai, jo India di growth layi zaroori hai, par isdi vakhri financial structure ate liabilities isnu ikk speculative outlook dindi hai. Investors nu isde risks ate potential turnaround da vadh-ghatt tolna pehuga, jo Damani ate Jhunjhunwala estate de faisle da vichar karda hai.